Alexander Spira, MD, PhD, Discusses Safety and Efficacy of Mobocertinib in EGFR ex20ins+ NSCLC Following Prior EGFR TKIs


CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how mobocertinib led to antitumor activity in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC) who were treated in a phase 1/2 study (NCT02716116) following prior tyrosine kinase inhibitor (TKI) therapy.


This is a subset analysis of a study of mobocertinib that has been going on for quite some time. It started as a phase 1 study, and this looked at a specific population of patients who got prior TKI therapy against [EGFR] exon 20. [Prior therapy] included experimental drugs, [such as] afatinib [Gilotrif], osimertinib [Tagrisso], and other [EGFR] exon 20 drugs like poziotinib. [The goal of the study was to] see how well [patients] did when they were treated with mobocertinib.

What we learned from this study is that patients who got prior TKI were able to benefit from mobocertinib, which was good news. Some of these TKIs were specific against [EGFR] exon 20, such as poziotinib, while others were not necessarily [EGFR] exon 20 specific, but more broad TKIs such as afatinib or osimertinib. My take home on this is that there is at least some evidence of efficacy of mobocertinib in patients who got other TKIs prior [to treatment] so we’re hoping that mobocertinib serves as a best in class compared to the other TKIs that are out there.


Spira A, Ramalingam SS, Neal J, et al. Mobocertinib in EGFR exon 20 insertion-positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract OA15.01.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content